

Brand name drugs—Cont.

Exclusivity period from imports, new drugs—*Cont.*

Contractual obligations, company-by-company commitments, Bill

C-22 research definition omitting, etc. 1:23-5; 3:9, 13-5, 27, 31-2, 54-5, 64, 70; 5:30-2; 6:20, 27, 33, 39, 78; 7:5, 10; 8:9, 52-3, 55; 9:13-5, 26, 35, 44-5; 10:8, 13-4, 16-7, 40; 11:12, 27-8, 41-3, 70; 12:7-9, 14-5, 32-9, 44-5, 47, 49, 54; 13:7, 11-2, 15, 21-5, 28-9, 39, 41, 43, 46; 14:12-5, 50-2, 57, 61; 15:10-1, 13, 19, 21, 34-5, 38-40; 15:48-9; 16:17-9, 22, 24, 82-7; 17:22-5

Regulation 2900 inclusion, proposal, 15:25; 17:23

Science Council of Canada recommendation, 13:40-2; 16:85

De facto extension, brand loyalties, detail men promoting, 6:55-6

Eastman report, four year proposed exclusivity period, 5:19; 8:61, 64; 11:77-8; 14:54-5; 15:86, 88

Fine chemicals provision, Bill C-22 second draft removing, 1:20-1; 3:13; 10:17-8

International standards, 17 year exclusivity period, etc., 1:12, 33; 3:14, 54, 59-60; 5:16, 19, 21; 7:5; 10:16; 12:59; 13:28; 14:9, 17-8, 43, 45, 57-8, 60; 16:64

United Kingdom, acceptable profit levels, defining, 14:57, 60, 71; 16:71

Notice of compliance, timing, exclusivity periods extending, 11:22-3, 26-7, 29; 14:22, 52; 15:14, 93

Prices, effect, 1:12-3; 3:41; 5:17, 30; 14:22

Industry

Contribution, 14:7

Monopoly power, 15:41, 72

Intellectual property protection, Bill C-22 providing, 1:11, 35, 45;

3:6, 42-4, 46-7, 49, 51, 54, 67, 69-70; 5:22, 25-6, 41; 6:79, 85;

7:18; 8:17, 20-1; 9:14; 10:6-7, 14-5, 44; 11:56, 62; 12:17-8, 23,

28, 38, 44, 46, 50; 13:36-7, 41; 15:19, 31; 16:64

Market share, 1:12; 7:5; 14:7, 18, 56

Multinational corporations' dominance/influence, 1:19-20; 3:9; 6:49

Profit levels, Bill C-22 increasing, 5:12, 17; 7:5; 8:21; 9:25, 27, 49;

10:7, 47-8; 10:7-8, 27, 29, 33, 47-8; 11:6, 52, 55, 68; 12:8, 48; 15:86

Excess cash, uses, *Globe and Mail* article, 11:7-8; 15:91-2, 99

Promotion expenses, 9:32-3, 38; 11:72-5

See also Brand name drugs—Exclusivity period from imports, *De facto* extension

Research and development record, new product innovations, pre

1969/post 1969, etc., 3:17-8, 42-4, 49, 57-8, 68-9; 6:41-3, 79; 7:6, 8-11, 16-7; 9:18, 39, 50; 10:26, 42-3; 11:9-10, 44-5, 67-8, 76-7; 12:10-1, 35; 13:39; 14:16, 29, 57, 61; 15:55, 59, 73, 91

Compulsory licensing restrictions, 5:21, 31; 8:67; 9:14; 14:34-5

Expenditures, doubling to 10% by 1995, industry promises,

3:45-7, 64-5, 69-70; 6:38-9, 46; 9:20; 10:6, 45; 11:7, 9-10, 17,

45-6; 12:35; 13:15, 36; 14:8, 12, 68; 15:33-4, 42

Education support, proposal, 15:47

Information, requesting, 3:64-5

Royalty system incentive, Eastman report recommendation,

5:19-20, 22, 32; 9:13-4, 18-20; 10:14-5, 43; 11:71, 76; 12:49;

14:56, 64-5; 15:26, 30; 16:86-7

World product mandate, speculating, 3:72

See also Drugs and pharmaceuticals industry—Research and development

United States, price comparison, 8:6

See also Generic drugs—Prices; Health care—Universality; Terry

Fox Medical Research Foundation; Universities—Research and development

Bury, John (Community Health Co-operative Federation of Saskatchewan)

Patent Act (amdt.)(Bill C-22), 11:3, 66-7, 70, 72-4, 76-9

Cabella, Mr.

References, 1:21

Caisse de dépôt du Québec, 1:34

Calenti, Luciano (Canadian Drug Manufacturers Association)

Patent Act (amdt.)(Bill C-22), 3:3, 6-14, 16-7, 20-4, 26-8, 30-5, 39

References, 1:20-1

See also Committee—Witnesses, Scheduling

Calgary Research and Development Authority

Background, 5:45-6

See also Witnesses

Canada Health Act, 12:76

See also Drugs and pharmaceuticals—Costs/prices, Compulsory licensing; Health care

Canadian Association of Social Workers *see* Witnesses

Canadian Automobile Workers Union

Drug plan benefits, etc., 14:23-4

Legislation, Bill C-22 opposing, Mulroney telegram, 14:20, 22

See also Green Shield Prepaid Services Inc.; Witnesses

Canadian Cancer Society

Legislation, Bill C-22 reservations, PMAC lobbying pressure, etc., 16:20-3, 25

See also Patent Act (amdt.)(Bill C-22)—References, Sunset clause

Canadian Cardiovascular Society

Background, 14:10, 16

See also Witnesses

Canadian Chamber of Commerce

Free trade negotiations, supporting, 8:20

Legislation, Bill C-22 support, 8:19, 22

See also Witnesses

Canadian Council on Social Development

Background, 6:66-7

See also Witnesses

Canadian Diabetes Association

Background, research projects, etc., 14:53

See also Witnesses

Canadian Drug Manufacturers Association

Andre meeting, 3:13, 61

Public, representing, claims, 3:58

Research and development commitments, information requesting, 3:13-4

See also Drugs and pharmaceuticals—Costs/prices; Witnesses

Canadian Federation of Biological Societies

Funding, need, 11:15

Legislation, Bill C-22 support, wavering, 11:9; 12:10, 38

See also Committee—Witnesses, Inviting

Canadian Health Coalition

Andre meeting, Bill C-22, 7:7, 18

Background, 7:17

Study, 11:60

See also Witnesses

Canadian Hospital Association

Legislation, Bill C-22 position, views soliciting, 9:32

See also Witnesses

Briefs *see* Appendices; Procedure and Committee business

Brossard report *see* Biotechnology industry—Stimulating